Preferred Label : Afatinib;
MeSH definition : A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of
epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of
metastatic NON-SMALL CELL LUNG CANCER.;
MeSH synonym : (2E)-N-(4-(3-Chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide;
MeSH hyponym : BIBW 2992 MA2; BIBW-2992MA2; BIBW 2992MA2; BIBW2992 MA2; BIBW2992; BIBW-2992;
MeSH CAS label : 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(((3S)-tetrahydro-3-furanyl)oxy)-6-quinazolinyl)-4-(dimethylamino)-,
(2E)-;
MeSH Related Number : 850140-72-6 (Afatinib); V1T5K7RZ0B;
Wikipedia link : https://en.wikipedia.org/wiki/Afatinib;
UNII : 41UD74L59M;
Origin ID : D000077716;
UMLS CUI : C2987648;
ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Currated CISMeF NLP mapping
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of
epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of
metastatic NON-SMALL CELL LUNG CANCER.
https://www.has-sante.fr/jcms/p_3189044/fr/giotrif
2020
false
false
false
France
Afatinib
afatinib dimaleate
afatinib
risk factors
afatinib dimaleate
continuity of patient care
insurance, health, reimbursement
carcinoma, non-small-cell lung
bronchial neoplasms
administration, oral
protein kinase inhibitors
Gastrointestinal perforation
intestinal perforation
evaluation of the transparency committee
Afatinib
---
https://www.has-sante.fr/jcms/p_3112642/fr/giotrif
2019
false
false
false
France
Afatinib
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2640689/fr/giotrif
2016
false
false
false
France
French
administration, oral
afatinib
afatinib
Afatinib Dimaleate
afatinib
evaluation of the transparency committee
protein kinase inhibitors
protein kinase inhibitors
protein-tyrosine kinases
Substance with protein-tyrosine kinase inhibitor mechanism of action (substance)
carcinoma, non-small-cell lung
treatment outcome
mutation
adult
neoplasm metastasis
EGFR protein, human
Advanced Malignant Neoplasm
insurance, health, reimbursement
Progression-Free survival
Tyrosine Kinase Inhibitors
disease-free survival
quinazolines
quinazolines
ErbB Receptors
Afatinib
Afatinib
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-EGFR-erlotinib-gefitinib-afatinib
2016
false
false
false
France
French
guidelines for drug use
patients guideline
practice guideline
antineoplastic agents
antineoplastic agents
antineoplastic agents
administration, oral
Erlotinib Hydrochloride
Erlotinib Hydrochloride
Erlotinib Hydrochloride
erlotinib
protein kinase inhibitors
protein kinase inhibitors
protein kinase inhibitors
Drug-Related side effects and adverse reactions
continuity of patient care
drug monitoring
drug interactions
pregnancy
carcinoma, non-small-cell lung
interdisciplinary communication
afatinib
afatinib
afatinib
afatinib
gefitinib
Tyrosine Kinase Inhibitors
quinazolines
quinazolines
quinazolines
ErbB Receptors
Gefitinib
Gefitinib
Gefitinib
Afatinib
Afatinib
Afatinib
---
http://www.meddispar.fr/Medicaments/GIOTRIF-30-B-28/(type)/letter/(value)/G/(cip)/3400927565700
2014
false
true
false
France
French
drug information
afatinib
administration, oral
drug prescriptions
legislation, drug
afatinib
continuity of patient care
drug monitoring
quinazolines
Afatinib
---
http://www.meddispar.fr/Medicaments/GIOTRIF-40-B-28/(type)/letter/(value)/G/(cip)/3400927565878
2014
false
true
false
France
French
drug information
administration, oral
legislation, drug
drug prescriptions
continuity of patient care
drug monitoring
afatinib
afatinib
quinazolines
Afatinib
---
http://www.meddispar.fr/Medicaments/GIOTRIF-20-B-28/(type)/letter/(value)/G/(cip)/3400927565649
2014
false
true
false
France
French
drug information
administration, oral
drug prescriptions
legislation, drug
continuity of patient care
drug monitoring
afatinib
afatinib
quinazolines
Afatinib
---
http://www.has-sante.fr/portail/jcms/c_1730855/fr/giotrif-50-mg-comprime-afatinib-inhibiteur-de-tyrosine-kinase
http://www.has-sante.fr/portail/jcms/c_1730855/fr/giotrif-afatinib-inhibiteur-de-tyrosine-kinase
2014
false
false
false
France
French
administration, oral
afatinib
afatinib
Afatinib Dimaleate
afatinib
evaluation of the transparency committee
guidelines for drug use
protein kinase inhibitors
protein kinase inhibitors
protein-tyrosine kinases
Substance with protein-tyrosine kinase inhibitor mechanism of action (substance)
carcinoma, non-small-cell lung
treatment outcome
mutation
adult
neoplasm metastasis
EGFR protein, human
Advanced Malignant Neoplasm
insurance, health, reimbursement
randomized controlled trials as topic
Progression-Free survival
Tyrosine Kinase Inhibitors
disease-free survival
quinazolines
quinazolines
ErbB Receptors
Afatinib
Afatinib
---
http://www.meddispar.fr/Medicaments/GIOTRIF-50-B-28/(type)/letter/(value)/G/(cip)/3400927565939
2014
false
true
false
France
French
drug information
administration, oral
drug prescriptions
legislation, drug
afatinib
afatinib
continuity of patient care
drug monitoring
quinazolines
Afatinib
---
https://www.ema.europa.eu/medicines/human/EPAR/Giotrif
2013
false
United Kingdom
French
English
drug approval
europe
treatment outcome
afatinib
drug monitoring
continuity of patient care
administration, oral
adult
carcinoma, non-small-cell lung
neoplasm metastasis
carcinoma, non-small-cell lung
mutation
drug interactions
pregnancy
breast feeding
contraception
fertility
controlled clinical trials as topic
drug evaluation, preclinical
summary of product characteristics
package leaflet
syndication feed
quinazolines
quinazolines
afatinib
afatinib
ErbB Receptors
Afatinib
Afatinib
---
